Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men

HIV Clinical Trials

Volumn 8, Issue 6, 2007, Pages 412-420

  Scott, James D ^a   Wolfe, Peter R ^b   Anderson, Peter ^c   Cohan, Gary R ^d   Scarsella, Anthony ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Robertson Diagnostic Center ^*

^d Pacific Oaks Medical Group   (United States)

Author keywords

HIV; Hypogonadism; Quality of life; Testosterone deficiency; Testosterone replacement therapy; Transdermal

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TESTOSTERONE; TESTOSTERONE CIPIONATE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GYNECOMASTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; LEAN BODY WEIGHT; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SKIN MANIFESTATION; TESTOSTERONE BLOOD LEVEL; WELLBEING;

ADMINISTRATION, TOPICAL; ADULT; GELS; HIV INFECTIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SERUM; TESTOSTERONE;

EID: 37349126950     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0806-412     Document Type: Article

References (34)

1. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278-1281.
2. Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991;73:1016-1025.
3. Tenover JL. Male hormone replacement therapy including "andropause." Endocrinol Metab Clin North Am. 1998;27:969-987.
4. Morley JE, Kaiser FE, Perry HM 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46:410-413.
5. Croxson TS, Chapman WE, Miller LK, et al. Changes in the hypothalamic-pituitary-gonadal axis in human immunodeficiency virus-infected homosexual men. J Clin Endocrinol Metab. 1989;68:317-321.
6. Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab. 1996;81:4051-4058.
7. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med. 1988;84(3 Pt 2):611-616.
8. Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in the HIV wasting syndrome. J Acquir Immune Defic Syndr. 1994;7:46-51.
9. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract. 2002;8:440-456.
10. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA. 2000;283:763-770.
11. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;129:18-26.
12. Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab. 1998;83:3155-3162.
13. Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J Clin Psychopharmacol. 1999;19:19-27.
14. Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab. 2000;85:2839-2853.
15. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-2098.
16. Cofrancesco J Jr, Whalen JJ 3rd, Dobs AS. Testosterone replacement treatment options for HIV-infected men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:254-265.
17. Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84:3469-3478.
18. Matsumoto AM. Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am. 1994;23:857-875.
19. Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 1980;51:1335-1339.
20. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 1982;37:425-430.
21. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab. 2000;85:964-969.
22. Depo®-Testosterone (testosterone cypionate) Full Prescribing Information. Kalamazoo, MI: Pharmacia & Upjohn; 2002.
23. AndroGel® (testosterone gel) Full Prescribing Information. Marietta, GA: Solvay Pharmaceuticals, Inc.; 2005.
24. Nankin HR. Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril. 1987;47:1004-1009.
25. Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85:4500-4510.
26. Technical Insert. DPCs Coat-a-Count® Free Testosterone assay. March 18, 2005.
27. Cella DF, McCain NL, Peterman AH, Mo F, Wolen D. Development and validation of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1996;5:450-463.
28. Peterman AH, Cella D, Mo F, McCain N. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual Life Res. 1997;6:572-584.
29. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:141-147.
30. Badia X. The measurement of health-related quality of life in prospective drug therapy studies in HIV-infected patients. AIDS Rev. 1999;1:213-220.
31. Collazos J, Martinez E, Mayo J, Ibarra S. Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy. AIDS. 2002;16:934-937.
32. Inaba T, Fischer NE, Riddick DS, Stewart DJ, Hidaka T. HIV protease inhibitors saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol Let. 1997;93:215-219.
33. WHO (World Health Organization). Human immunodeficiency virus and acquired immunodeficiency syndrome (Chapter XII). In: Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
34. Clay PG. Program savings associated with switching testosterone intramuscular injections to topical gel in HIV infected males. Curr Med Res Opin. 2004;20:461-468.